参考文献/References:
[1] 刘红举,于炎冰,任鸿翔,等.改良Foerster-Dandy手术治疗痉挛性斜颈的长期随访结果(附550例报告)[J].中华神经外科杂志,2019,35(1):6-9.
[2] LAHUE S C,ALBERS K,GOLDMAN S,et al.Cervical dystonia incidence and diagnostic delay in a multiethnic population[J].Mov Disord,2020,35(3):450-456.
[3] 李宏锴,黄书岚,张向阳.痉挛性斜颈的诊疗研究进展[J].中国医药导报,2018,15(11):37-40.
[4] 谭丽莉,徐帆,孙月,等.实时剪切波弹性成像和彩色脉搏波成像技术在Ⅱ型糖尿病患者颈动脉硬度中的应用研究[J].重庆医学,2022,51(21):3634-3638.
[5] BRANDENBURG J E,EBY S F,SONG P,et al.Quantifying effect of onabotulinum toxin A on passive muscle stiffness in children with cerebral palsy using ultrasound shear wave elastography[J].Am J Phys Med Rehabil,2018,97(7):500-506.
[6] 窦艳,帅晓红,刘媛.实时剪切波超声弹性成像在BIRADS 3～5类病变的应用研究[J].影像研究与医学应用,2021,5(13):82-83.
[7] 宋烨,张天杰,李园,等.实时剪切波弹性成像技术对A型肉毒毒素治疗扭转型痉挛性斜颈的应用评价[J].河北医药,2019,41(2):237-239.
[8] TSUI J K,EISEN A,STOESSL A J,et al.Double-blind study of botulinum toxin in spasmodic torticollis[J].Lancet,1986,2(8501):245-247.
[9] HOK P,HVIZDOSOVÁ L,OTRUBA P,et al.Botulinum toxin injection changes resting state cerebellar connectivity in cervical dystonia[J].Sci Rep,2021,11(1):8322.
[10] 张杰颖.痉挛性斜颈发病机制的结构与功能神经影像学研究[D].北京:北京协和医学院,2015.
[11] HAYASHI D,OHSHIMA S,ISOBE S,et al.Increased(99m)Tc-sestamibi washout reflects impaired myocardial contractile and relaxation reserve during dobutamine stress due to mitochondrial dysfunction in dilated cardiomyopathy patients[J].J Am Coll Cardiol,2013,61(19):2007-2017.
[12] MASUDA A,YOSHINAGA K,NAYA M,et al.Accelerated(99m)Tc-sestamibi clearance associated with mitochondrial dysfunction and regional left ventricular dysfunction in reperfused myocardium in patients with acute coronary syndrome[J].EJNMMI Res,2016,6(1):41.
[13] NEMCOVA A,JIRKOVSKA A,DUBSKY M,et al.Perfusion scintigraphy in the assessment of autologous cell therapy in diabetic patients with critical limb ischemia[J].Physiol Res,2018,67(4):583-589.
[14] CHEN S,ISSA M D,WANG C,et al.[99mTc]MIBI SPECT/CT for identifying dystonic muscles in patients with primary cervical dystonia[J].Mol Imaging Biol,2020,22(4):1054-1061.
[15] FENG L,ZHANG Z,MALAM DJIBO I,et al.The efficacy of single-photon emission computed tomography in identifying dystonic muscles in cervical dystonia[J].Nucl Med Commun,2020,41(7):651-658.
[16] 罗梦,周国平,杨路,等.表面肌电图在脑卒中后运动功能障碍康复中的应用[J].中国康复,2017,32(1):67-70.
[17] 薛泳华,徐侃.痉挛性斜颈的外科治疗及其相关解剖特点[J].安徽医药,2018,22(5):882-884.
[18] 郁正红,徐宋宇,李建华.A型肉毒毒素注射联合针灸干预治疗旋转型痉挛性斜颈疗效观察[J].浙江中西医结合杂志,2017,27(8):675-678.
[19] CASTAGNA A,ALBANESE A.Management of cervical dystonia with botulinum neurotoxins and EMG/ultrasound guidance[J].Neurol Clin Pract,2019,9(1):64-73.
[20] JOST W H,HEFTER H,STENNER A,et al.Rating scales for cervical dystonia:a critical evaluation of tools for outcome assessment of botulinum toxin therapy[J].J Neural Transm(Vienna),2013,120(3):487-496.
[21] 李薇薇,武连仲.针药并用治疗痉挛性斜颈临床观察[J].上海针灸杂志,2015,34(2):143-144.
[22] 孟佑强,薛泳华,浦奔放,等.副神经切断联合远端毁损术治疗痉挛性斜颈的临床疗效分析[J].现代生物医学进展,2016,16(19):3673-3675.
[23] POEWE W,DEUSCHL G,NEBE A,et al.What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia?Results of a double blind,placebo controlled,dose ranging study using Dysport.German Dystonia Study Group[J].J Neurol Neurosurg Psychiatry,1998,64(1):13-17.
[24] ANANDAN C,JANKOVIC J.Botulinum toxin in movement disorders:an update[J].Toxins(Basel),2021,13(1):42.
[25] ESPAY A J,TROSCH R,SUAREZ G,et al.Minimal clinically important change in the Toronto Western spasmodic torticollis rating scale[J].Parkinsonism RelatDisord,2018,52:94-97.
[26] 隆昱洲,雷进,罗丽华,等.低频重复经颅磁刺激在痉挛性斜颈治疗中的应用价值[J].实用医学杂志,2015,31(1):54-56.
[27] SARYYEVA A,CAPELLE H H,KINFE T M,et al.Pallidal deep brain stimulation in patients with prior bilateral palli-dotomy and selective peripheral denervation for treatment of dystonia[J].Stereotact Funct Neurosurg,2021,99(1):1-5.
[28] PINTÉR D,JANSZKY J,KOVÁCS N.Minimal clinically important differences for Burke-Fahn-Marsden dystonia rating scale and 36-item short-form health survey[J].Mov Disord,2020,35(7):1218-1223.
[29] SARYYEVA A,CAPELLE H H,KINFE T M,et al.Pallidal deep brain stimulation in patients with prior bilateral pallidotomy and selective peripheral denervation for treatment of dystonia[J].Stereotact Funct Neurosurg,2021,99(1):1-5.
[30] COMELLA C L,LEURGANS S,WUU J,et al.Rating scales for dystonia:a multicenter assessment[J].Mov Disord,2003,18(3):303-312.
[31] TAKAHASHI M,SHIMOKAWA T,KOH J,et al.Efficacy and safety of istradefylline in patients with Parkinson's di-sease presenting with postural abnormalities:results from a multicenter,prospective,and open-label exploratory study in Japan[J].J Neurol Sci,2022,432:120078.
[32] BIRSKA J,ZIELINSKI P,BIRSKI M,et al.Assessment of cognitive functioning after pallidotomy in patients with primary dystonia[J].Stereotact Funct Neurosurg,2016,94(1):33-40.
[33] CHAN J,BRIN M F,FAHN S.Idiopathic cervical dystonia:clinical characteristics[J].Mov Disord,1991,6(2):119-126.
[34] DRESSLER D,KUPSCH A,SEITZINGER A,et al.The dystonia discomfort scale(DDS):a novel instrument to monitor the temporal profile of botulinum toxin therapy in cervical dystonia[J].Eur J Neurol,2014,21(3):459-462.
[35] DRESSLER D,PAUS S,SEITZINGER A,et al.Long-term efficacy and safety of incobotulinumtoxin A injections in patients with cervical dystonia[J].J Neurol Neurosurg Psychiatry,2013,84(9):1014-1019.
[36] CANO S J,WARNER T T,LINACRE J M,et al.Capturing the true burden of dystonia on patients:the cervical dystonia impact profile(CDIP-58)[J].Neurology,2004,63(9):1629-1633.
[37] CANO S J,HOBART J C,EDWARDS M,et al.CDIP-58 can measure the impact of botulinum toxin treatment in cervical dystonia[J].Neurology,2006,67(12):2230-2232.
[38] MÜLLER J,WISSEL J,KEMMLER G,et al.Craniocervical dystonia questionnaire(CDQ-24):development and validation of a disease-specific quality of life instrument[J].J Neurol Neurosurg Psychiatry,2004,75(5):749-753.
(收稿日期:2022-10-09 本文编辑:吕宁)